Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from FDA

The widespread use of baby formula across America has come under the spotlight as a national shortage has sparked an infant nutritional crisis.

Axios

Baby formula shortage puts spotlight on how America feeds its young

The widespread use of baby formula across America has come under the spotlight as a national shortage has sparked an infant nutritional crisis.

Axios

Despite Congress’ efforts, it’ll take time to refill the baby bottles - Roll Call

Lawmakers are scrambling to end the formula shortage, but experts say it will be months before families will feel an impact.

Roll Call

From analysis to the latest developments in health,
read the most diverse news in one place.

As Red Cross moves to pricey blood treatment method, hospitals call for more choice

Americans generally don’t spend much time thinking about the nation’s blood supply.

Tribune News Service

A love letter to the perfect pasta shape

They bounce, they squeak, they whistle, they fling sauce in unpredictable directions — and I love it

Salon

With old-school technology, can Novavax win over COVID vaccine skeptics?

Since their debut just 18 months ago, three COVID-19 vaccines have saved an estimated 2.2 million American lives, changed the trajectory of a pandemic and inspired all manner of conspiracy theories.

Los Angeles Times

FDA Declines Emergency Use Request For An Antidepressant As COVID-19 Treatment

The FDA has decided not to authorize fluvoxamine, an antidepressant, to treat COVID-19. The agency that data has not shown the drug to be an effective therapeutic for fighting the virus. "Based on the review of available scientific evidence, the FDA has determined that the data are insufficient to conclude that fluvoxamine…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Sorrento Starts Mid-Stage Study Of Abivertinib In Prostate Cancer

The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ:SRNE) investigational new drug application (IND) for Abivertinib (Fujovee) for Phase 2 MAVERICK study in metastatic castrate-resistant prostate cancer (mCRPC). The MAVERICK study will be conducted in a partnership with the Prostate Cancer Clinical Trials Consortium and will enroll participants with both abiraterone-naïve and abiraterone-progressing…

Benzinga

Why is there a baby formula shortage in the US?

With children hospitalised and parents paying up to $100 for a can, the president has now invoked a wartime measure to try to ensure there is enough formula to feed America’s babies

The Independent UK

House Democrats release $28 million aid bill to address baby formula shortage

The money is intended to help the FDA prepare for potential future shortages.

Axios

FDA authorizes first COVID booster for children ages 5 to 11

The Food and Drug Administration expanded authorization of Pfizer-BioNTech's COVID vaccine to enable kids ages 5 to 11 who were vaccinated at least five months ago to get a third shot.

WEKU

FDA Gives Nod To First Nonprescription COVID-19 Test That Also Detects Flu, RSV

The FDA has authorized the first nonprescription test to detect Covid-19, influenza, and respiratory syncytial virus (RSV). The test, called the Labcorp Seasonal Respiratory Virus RT-PCR DTC Test, was developed by Laboratory Corp of America Holdings (NYSE:LH). It can be sold directly to consumers online or at retail. A person can self-collect a nasal…

Benzinga

FDA May Authorize Pfizer-BioNTech's COVID-19 Booster For 5-11 Year Kids Soon: NYT

The FDA is expected to authorize a booster shot of Pfizer Inc (NYSE:PFE) / BioNTech SE's (NASDAQ:BNTX) COVID-19 vaccine for children aged 5 to 11 probably by today, the New York Times reported, citing people familiar with the matter. The companies submitted an application to the FDA for authorization last month. They have cited data from…

Benzinga

Applied Genetic's Vision Loss Gene Therapy Shows Encouraging Safety, Efficacy At Three Months

Applied Genetic Technologies Corp (NASDAQ:AGTC) reported three-month interim data from its ongoing Phase 2 Skyline trial of AGTC-501 for X-linked retinitis pigmentosa (XLRP), an inherited condition causing progressive vision loss in boys and young men. AGTC-501 is a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene. There were robust…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

'Mother Like' Kim Jong-Un Personally Tastes Baby Formula To Ensure Quality: North Korea Mocks US Shortages

Taking a dig at the U.S. formula shortages, a bizarre news article from North Korean state media randomly claimed that Kim Jong Un personally oversaw the perfection of the nation's baby formula recipe.

Benzinga

73 Biggest Movers From Yesterday

Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday.

Benzinga

US Baby Formula Crisis Could See Some Relief As FDA, Abbott Agree On Deal

The baby formula shortage that has morphed into a crisis in the U.S. could soon see some relief following an agreement between market leader Abbott Laboratories (NYSE: ABT) and the Food and Drug Administration.

WEKU

FDA announces plans to ease the shortage of baby formula

Abbott, one of the largest formula-makers in the U.S., has reached an agreement with the government to bring a closed factory back on line. And the FDA is easing some restrictions on imported formula.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Abbott Nutrition strikes deal with FDA to restart factory linked to baby formula shortage

Shelves across US now empty of essential product

Chicago Sun-Times

Deal reached to reopen baby formula plant, Abbott says

The company, headquartered in Chicago, did not immediately detail terms of the agreement with the Food and Drug Administration, which has been investigating safety concerns at the firm’s Sturgis, Michigan, plant.

Chicago Tribune

Abbott enters into agreement with FDA, outlining terms for resuming infant formula production at Michigan site

CHICAGO — Abbott Laboratories and the U.S. Food and Drug Administration have come to an agreement on the steps the company needs to take before it can restart production of infant formula at a Michigan facility, Abbott said Monday.

Benzinga

Abbott Spent $5B On Stock Buybacks Instead Of Fixing Its Baby Formula Factory

The fear of not knowing where your child’s next meal comes from is something that no parent should face. But, because of a recall of Abbott Laboratories’ (NYSE: ABT) Similac and other popular baby formula brands, stores throughout the nation are limiting how much formula parents can buy.

StockNews.com

3 Healthcare Stocks That Pay Dominant Dividends

Despite heightened market volatility, the healthcare industry is expected to grow significantly in 2022 amid surging chronic diseases worldwide, an aging population, increasing healthcare expenditure, and numerous medical advancements. So, we think it could be wise to invest in fundamentally sound healthcare stocks Gilead (GILD), Takeda (TAK), and GlaxoSmithKline (GSK).…

Benzinga

Why Are Akebia Therapeutics Shares Falling Today?

Akebia Therapeutics Inc (NASDAQ:AKBA) and Otsuka Holdings (OTC: OTSKY) separately announced to call for licensing and co-development agreement for vadadustat. Otsuka sent a written notice to Akebia on May 12 that the partnership had been terminated. Akebia said in an SEC filing filed Friday that the termination will go into effect in a year.…

Benzinga

Sanofi Says Sarclisa Shows 'Unprecedented Median Progression-Free Survival' In Multiple Myeloma Patients

Sanofi SA (NASDAQ:SNY) shared the latest results from the Phase 3 IKEMA trial evaluating Sarclisa (isatuximab) in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy. Sarclisa combined with carfilzomib and dexamethasone (Kd) demonstrated a median progression-free survival (mPFS) of 35.7 months, compared to 19.2 months in patients treated with Kd alone. …

1 … 209 210 211 212

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.